AMARIN CORP PLC\UK Net Income (Loss) Available to Common Stockholders, Diluted
AMARIN CORP PLC\UK (AMRN) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$7.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-07-29
- AMARIN CORP PLC\UK net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$7.65M.
- AMARIN CORP PLC\UK net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$10.51M.
- AMARIN CORP PLC\UK net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$1.22M.
- AMARIN CORP PLC\UK net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$7.74M.
- AMARIN CORP PLC\UK net income (loss) available to common stockholders, diluted for fiscal 2025 was -$38.80M.
- AMARIN CORP PLC\UK net income (loss) available to common stockholders, diluted for fiscal 2024 was -$82.18M.
- AMARIN CORP PLC\UK net income (loss) available to common stockholders, diluted for fiscal 2023 was -$59.11M.
- AMARIN CORP PLC\UK net income (loss) available to common stockholders, diluted for fiscal 2022 was -$105.80M, a 1468.91% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.65M 10-Q · filed 2026-07-29 | -$18.16M 10-Q · filed 2026-07-29 | -$19.39M derived: sum of 3 quarters · filed 2026-07-29 | -$27.12M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$10.51M 10-Q · filed 2026-04-29 | -$11.74M derived: sum of 2 quarters · filed 2026-04-29 | -$19.47M derived: sum of 3 quarters · filed 2026-04-29 | -$33.61M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$8.96M derived: sum of 2 quarters · filed 2026-03-02 | -$23.10M derived: sum of 3 quarters · filed 2026-07-29 | -$38.80M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$7.74M 10-Q · filed 2025-10-29 | -$21.88M derived: sum of 2 quarters · filed 2026-07-29 | -$37.57M 10-Q · filed 2025-10-29 | -$86.19M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$14.14M 10-Q · filed 2026-07-29 | -$29.84M 10-Q · filed 2026-07-29 | -$78.45M derived: sum of 3 quarters · filed 2026-07-29 | -$103.59M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$15.70M 10-Q · filed 2026-04-29 | -$64.31M derived: sum of 2 quarters · filed 2026-04-29 | -$89.45M derived: sum of 3 quarters · filed 2026-04-29 | -$87.93M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$48.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$73.75M derived: sum of 2 quarters · filed 2026-03-02 | -$72.23M derived: sum of 3 quarters · filed 2026-03-02 | -$82.18M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$25.13M 10-Q · filed 2025-10-29 | -$23.61M derived: sum of 2 quarters · filed 2025-10-29 | -$33.56M 10-Q · filed 2025-10-29 | -$39.35M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $1.52M 10-Q · filed 2025-07-30 | -$8.43M 10-Q · filed 2025-07-30 | -$14.21M derived: sum of 3 quarters · filed 2026-03-02 | -$33.52M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$9.95M 10-Q · filed 2025-05-07 | -$15.73M derived: sum of 2 quarters · filed 2026-03-02 | -$35.05M derived: sum of 3 quarters · filed 2026-03-02 | -$52.60M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$5.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$25.09M derived: sum of 2 quarters · filed 2026-03-02 | -$42.65M derived: sum of 3 quarters · filed 2026-03-02 | -$59.11M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$19.31M 10-Q · filed 2024-10-30 | -$36.87M derived: sum of 2 quarters · filed 2024-10-30 | -$53.33M 10-Q · filed 2024-10-30 | -$52.48M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-06-30 | -$17.56M 10-Q · filed 2024-07-31 | -$34.02M 10-Q · filed 2024-07-31 | -$33.16M derived: sum of 3 quarters · filed 2025-03-12 | -$38.30M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-03-31 | -$16.46M 10-Q · filed 2024-05-01 | -$15.60M derived: sum of 2 quarters · filed 2025-03-12 | -$20.74M derived: sum of 3 quarters · filed 2025-03-12 | |
| 2022-12-31 | $856.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$4.28M derived: sum of 2 quarters · filed 2025-03-12 | -$105.80M 10-K · filed 2025-03-12 | |
| 2022-09-30 | -$5.14M 10-Q · filed 2023-11-01 | -$106.66M 10-Q · filed 2023-11-01 | ||
| 2021-12-31 | $7.73M 10-K · filed 2024-02-29 | |||
| 2016-12-31 | -$27.45M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$43.23M derived: sum of 2 quarters · filed 2017-03-01 | -$56.58M derived: sum of 3 quarters · filed 2017-03-01 | -$86.35M 10-K · filed 2017-03-01 |
| 2016-09-30 | -$15.77M 10-Q · filed 2016-11-03 | -$29.13M derived: sum of 2 quarters · filed 2016-11-03 | -$58.90M 10-Q · filed 2016-11-03 | -$80.67M derived: sum of 4 quarters · filed 2017-03-01 |
| 2016-06-30 | -$13.35M 10-Q · filed 2016-08-04 | -$43.13M 10-Q · filed 2016-08-04 | -$64.90M derived: sum of 3 quarters · filed 2017-03-01 | -$97.22M derived: sum of 4 quarters · filed 2017-03-01 |
| 2016-03-31 | -$29.77M 10-Q · filed 2016-05-05 | -$51.54M derived: sum of 2 quarters · filed 2017-03-01 | -$83.86M derived: sum of 3 quarters · filed 2017-03-01 | -$146.72M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-12-31 | -$21.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$54.09M derived: sum of 2 quarters · filed 2017-03-01 | -$116.95M derived: sum of 3 quarters · filed 2017-03-01 | -$149.06M 10-K · filed 2017-03-01 |
| 2015-09-30 | -$32.32M 10-Q · filed 2016-11-03 | -$95.17M derived: sum of 2 quarters · filed 2016-11-03 | -$127.29M 10-Q · filed 2016-11-03 | -$146.95M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$62.85M 10-Q · filed 2016-08-04 | -$94.97M 10-Q · filed 2016-08-04 | -$114.63M derived: sum of 3 quarters · filed 2017-03-01 | -$145.07M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$32.11M 10-Q · filed 2016-05-05 | -$51.77M derived: sum of 2 quarters · filed 2017-03-01 | -$82.21M derived: sum of 3 quarters · filed 2017-03-01 | -$66.55M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$19.66M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$50.10M derived: sum of 2 quarters · filed 2017-03-01 | -$34.43M derived: sum of 3 quarters · filed 2017-03-01 | -$63.14M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$30.44M 10-Q · filed 2015-11-04 | -$14.78M derived: sum of 2 quarters · filed 2015-11-04 | -$43.48M 10-Q · filed 2015-11-04 | -$89.81M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $15.67M 10-Q · filed 2015-08-06 | -$13.04M 10-Q · filed 2015-08-06 | -$59.37M derived: sum of 3 quarters · filed 2016-02-25 | -$108.25M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | -$26.95M 10-Q · filed 2015-05-08 | -$75.04M derived: sum of 2 quarters · filed 2016-02-25 | -$123.92M derived: sum of 3 quarters · filed 2016-02-25 | -$176.68M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | -$48.09M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$96.97M derived: sum of 2 quarters · filed 2016-02-25 | -$149.73M derived: sum of 3 quarters · filed 2016-02-25 | -$214.16M 10-K · filed 2016-02-25 |
| 2013-09-30 | -$48.88M 10-Q · filed 2014-11-06 | -$101.64M derived: sum of 2 quarters · filed 2014-11-06 | -$166.07M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | -$52.76M 10-Q · filed 2014-08-07 | -$120.76M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | -$68.00M 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | -$179.18M 10-K · filed 2015-03-03 | |||
| 2011-12-31 | -$69.13M 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |